Medications for Endoscopy
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Endoscopy.
Found 5 Approved Drugs for Endoscopy
Nayzilam
Generic Name
Midazolam
Nayzilam
Generic Name
Midazolam
Form: Injection, Spray, Syrup
Method of administration: Nasal, Oral, Intravenous, Intramuscular
FDA approval date: June 20, 2000
Classification: Benzodiazepine
Midazolam HCl Syrup is indicated for use in pediatric patients for sedation, anxiolysis and amnesia prior to diagnostic, therapeutic or endoscopic procedures or before induction of anesthesia. Midazolam HCl syrup is intended for use in monitored settings only and not for chronic or home use. WARNINGS MIDAZOLAM HCL SYRUP MUST BE USED AS SPECIFIED IN THE LABEL. Midazolam is associated with a high incidence of partial or complete impairment of recall for the next several hours. CLINICAL PHARMACOLOGY.
Bludigo
Generic Name
Indigotindisulfonate
Bludigo
Generic Name
Indigotindisulfonate
Form: Injection
Method of administration: Intravenous
FDA approval date: September 06, 2022
Classification: Diagnostic Dye
BLUDIGO is indicated for use as a visualization aid in the cystoscopic assessment of the integrity of the ureters in adults following urological and gynecological open, robotic, or endoscopic surgical procedures. BLUDIGO is a diagnostic dye indicated for use as a visualization aid in the cystoscopic assessment of the integrity of the ureters in adults following urological and gynecological open, robotic, or endoscopic surgical procedures. ( 1 )
Clenpiq
Generic Name
Picosulfate
Clenpiq
Generic Name
Picosulfate
Form: Liquid
Method of administration: Oral
FDA approval date: March 29, 2023
Classification: Calculi Dissolution Agent
CLENPIQ is indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 9 years of age and older. CLENPIQ ® is a combination of sodium picosulfate, a stimulant laxative, and magnesium oxide and anhydrous citric acid, which form magnesium citrate, an osmotic laxative, indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients ages 9 years and older. ( 1 )
Glycol-3350
Brand Names
Peg-3350, GaviLyte, GaviLyte-N, electrolyteswith, GoLYTELY
Glycol-3350
Brand Names
Peg-3350, GaviLyte, GaviLyte-N, electrolyteswith, GoLYTELY
Form: Powder
Method of administration: Oral
FDA approval date: July 13, 1984
Classification: Osmotic Laxative
Polyethylene Glycol 3350 and electrolytes for oral solution, is a combination of PEG 3350, an osmotic laxative, and electrolytes indicated for cleansing of the colon in preparation for colonoscopy and barium enema X-ray examination in adults. Polyethylene Glycol 3350 and electrolytes for oral solution is indicated for bowel cleansing prior to colonoscopy and barium enema X-ray examination in adults.
Iothalamate meglumine
Brand Names
Conray, Cysto-Conray
Iothalamate meglumine
Brand Names
Conray, Cysto-Conray
Form: Injection
Method of administration: Intravascular, Ureteral
FDA approval date: October 14, 2003
Classification: Radiographic Contrast Agent
Conray is indicated for use in excretory urography, cerebral angiography, peripheral arteriography, venography, arthrography, direct cholangiography, endoscopic retrograde cholangiopancreatography, contrast enhancement of computed tomographic brain images, cranial computerized angiotomography, intravenous digital subtraction angiography and arterial digital subtraction angiography. Conray may also be used for enhancement of computed tomographic scans performed for detection and evaluation of lesions in the liver, pancreas, kidneys, abdominal aorta, mediastinum, abdominal cavity and retroperitoneal space. Continuous or multiple scans separated by intervals of 1 to 3 seconds during the first 30 to 90 seconds post-injection of the contrast medium (dynamic CT scanning) may provide enhancement of diagnostic significance, and may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions. In other cases, the contrast agent may allow visualization of lesions not seen with CT alone, or may help to define suspicious lesions seen with unenhanced CT. Subsets of patients in whom delayed body CT scans might be helpful have not been identified. Inconsistent results have been reported and abnormal and normal tissues may be isodense during the time frame used for delayed CT scanning. The risks of such indiscriminate use of contrast media are well known and such use is not recommended. At present, consistent results have been documented using dynamic CT techniques only.
Showing 1-5 of 5
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances